---
title: "Henlius Biotech Strikes Licensing Deal with Dr. Reddy's for Myeloma Drug"
date: "2025-02-07 17:34:31"
summary: "Shanghai Henlius Biotech agreed to license its anti-cancer injection HLX15 to Dr. Reddy's Laboratories in the US and 42 European countries. HLX15 is a recombinant anti-CD38 fully human monoclonal antibody injection and a daratumumab biosimilar developed by the company. It is indicated for treating multiple myeloma. Under the agreement, Dr...."
categories:
  - "MT Newswires"
lang:
  - "en"
translations:
  - "en"
tags:
  - "MT Newswires"
menu: ""
thumbnail: ""
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

Shanghai Henlius Biotech agreed to license its anti-cancer injection HLX15 to Dr. Reddy's Laboratories in the US and 42 European countries.

HLX15 is a recombinant anti-CD38 fully human monoclonal antibody injection and a daratumumab biosimilar developed by the company. It is indicated for treating multiple myeloma.

Under the agreement, Dr. Reddy's Laboratories is granted the license to manufacture and commercialize HLX15 in subcutaneous and intravenous forms across 43 markets.

Dr. Reddy's Laboratories will make an upfront payment of $33 million, plus $98.6 million in milestone payments and 8% of the annual net sales as royalties, a Thursday Hong Kong bourse filing said.

[MT Newswires](https://www.tradingview.com/news/mtnewswires.com:20250207:G2465035:0/)
